Jobs / United States / Regeneron Pharmaceuticals INC
Pharmacokineticist, PPK/PD
Regeneron Pharmaceuticals INC · 🇺🇸 TARRYTOWN
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Regeneron Pharmaceuticals INC
The US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Regeneron Pharmaceuticals INC →
About the role
Build Our Future Together At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Pharmacokineticist for PPK/PD to serve as a senior independent contributor in the Translational Pharmacokinetics and Pharmacodynamics (TPK/PD) Group, taking ownership of PK/PD analyses end-to-end and serving as a pharmacokinetics point of contact across assigned studies. This person will independently plan and execute non-compartmental and compartmental PK/PD analyses in support of nonclinical and (potentially) clinical studies using Phoenix WinNonlin and other analysis software, and will prepare and quality-control standardized datasets from CRO and internal bioanalytical data for regulatory submission. This person will lead PK/TK protocol design/input, support CRO studies, produce Pharmacometrics deliverables and regulatory tables/figures/listings, contribute to standard-setting and best practices for the group, and mentor and provide technical guidance to junior analysts, following all SOPs to ensure GxP/GLP compliance. When & Where: This role will sit at our Tarrytown, NY office and is expected to be on-site 4 days per week. Discover Your Role: • Independently leads, performs, and takes ownership of non-compartmental PK and compartmental PK/PD analyses in support of nonclinical and (potentially) clinical studies, according to GxP as appropriate, and serves as the pharmacokinetics point of contact and lead analyst for assigned studies. • Conducts compliance-related activities (SOPs, etc.); ensures regulatory-submission conformance, data integrity, and GxP compliance; adheres to controlled SOPs; helps set group standards by authoring/revising SOPs and providing senior compliance review of others' deliverables; and meets mandatory-training and data-confidentiality requirements. • Owns the preparation, quality control, and senior review of standardized CDISC SEND datasets (e.g., PC/PP domains and associated SUPPQUAL) from CRO and internal bioanalytical data, with auditable, source-traceable derivations that conform to controlled terminology and regulatory-submission standards, and sets and maintains the dataset standards and conventions the group follows. • Owns and leads CRO study support; tracks study requirements, project priorities, status, and milestones; serves as the primary PK point of contact and liaison to CROs and functional groups; and drives coordination across the study lifecycle. • Independently owns and executes a broad array of work supporting department priorities in routine and non-routine Pharmacometrics deliverables on study design, analysis, and reporting, and sets methodology and best-practice standards for the group. • Produces and formats tables and listings (TFLs), including PK concentration and parameter summaries, for regulatory documents using validated tools (e.g., Phoenix WinNonlin, R), and owns, sets, and reviews against the group's consistent, submission-ready presentation standard. • Produces and reviews figures and graphical outputs (e.g., concentration-time profiles) for study reports and regulatory submissions using validated tools, and owns and sets the group's graphical presentation standard. This Role Requires: • Bachelors degree with 5-7 years of professional experience, or a Masters degree with 3-5 years of professional experience • Strong, in-depth understanding of pharmacokinetics concepts and techniques • Proficient in relevant software, including Phoenix WinNonlin; knowledge of NLME/population PK a plus • Experience in animal PK/TK studies, including protocol design & study conduct • Able to clearly describe and perform advanced pharmacometric techniques, interpret results independently, and mentor and provide techn